Zilico Ltd.

Rutherford House, Pencroft Way, Manchester Science Park , M15 6SZ Manchester
United Kingdom

Telephone +44 161 8267840-267840
info@zilico.co.uk

This company is co-exhibitor of
Association of British Healthcare Industries Ltd.

Trade fair hall

  • Hall 16 / F18-5
 Interactive Plan

Hall map

MEDICA 2016 hall map (Hall 16): stand F18-5

Fairground map

MEDICA 2016 fairground map: Hall 16

Company news

Date

Topic

Download

Nov 13, 2016

UK cervical cancer diagnostic system to be piloted in India as part of TechEmerge’s programme

Zilico Ltd – a developer of a pioneering cervical cancer diagnostic system - has been selected by the IFC, a member of the World Bank Group, to be part of a unique program across India.

TechEmerge is the first programme of its kind that brings together proven technology companies such as Zilico, with leading healthcare providers in emerging markets.

Chosen from 330 innovators across 29 countries, the inaugural program will see the company working with International Oncology Services, with the aim of increasing the early detection of cervical cancer across India and quickly enabling treatment.

ZedScan™ uses the science of Electrical Impedance Spectroscopy (EIS) to detect the development of pre-cancerous abnormalities of the cervix.

The portable, handheld device is already being used in hospitals across the UK and other countries, provides a more accurate diagnosis in real-time, which assists clinicians with better patient management.

In a recent review of over 1500 women referred to an UK colposcopy clinic, the adoption of ZedScan resulted in a significant increase in disease detection and improvements in clinical performance.

he patient case study revealed a 13% increase in detection of high-grade disease (HGCIN) across all patients, with 50% increase reported in women with low-grade cytology. In 92% of these cases, disease was confirmed with a single biopsy.

Cervical cancer, which is caused by Human Papillomavirus infection, is the leading cancer in Indian women. It is the second most common cancer in women worldwide.

It is estimated there are approximately 132,000 new cases diagnosed and 74,000 deaths annually in India, which accounts for nearly a third of the global cervical cancer deaths.

Although colposcopy is an important method in detecting cervical cancer, in practice, the procedure has not drastically changed over the last 90 years, and diagnosis depends on the subjective assessment of visual indicators by the clinician.

Using ZedScan as an adjunct to the existing colposcopy procedure will help clinicians better manage patients and help avoid unnecessary biopsies, treatments and repeat follow-up appointments.

Colposcopy referrals are also expected to increase dramatically following the introduction of HPV screening and ZedScan can provide a cost-effective means to accommodate this growth.

Sameer Kothari, Chief Executive of Zilico Ltd, said: “We are delighted that Zilico has been chosen as one of TechEmerge’s successful matches and look forward to working with International Oncology Services to implement ZedScan and help improve healthcare delivery in India.”

To find out more visit Zilico at MEDICA 2016 in Hall 16, Stand F18-5.

 

More Less

Oct 30, 2016

Pioneering diagnostic system set to change the face of colposcopy to be showcased at MEDICA 2016

A pioneering diagnostic system that is having a significant impact on the changing clinical pathway for cervical cancer will be on display at MEDICA 2016 by multi-award winning company, Zilico Ltd.

ZedScan™ is a portable, handheld device that uses patented Electrical Impedance Spectroscopy (EIS) to detect the development of pre-cancerous abnormalities of the cervix, known as cervical intraepithelial neoplasia (CIN).

The innovative system not only removes subjectivity and increases accuracy, but it also helps clinicians manage growing colposcopy referrals generated by the introduction of primary HPV testing.

In a recent review of over 1500 women referred to an NHS colposcopy clinic, the adoption of ZedScan resulted in a significant increase in disease detection and improvements in clinical performance.

The patient case study revealed a 13% increase in detection of high-grade disease (HGCIN) across all patients, with 50% increase reported in women with low-grade cytology. In 92% of these cases, disease was confirmed with a single biopsy.

If rolled out across the UK, this would equate to an additional 200 women being identified with HGCIN every week, or approximately 10,000 women each year who can therefore be diagnosed and treated much earlier. Thus preventing disease from developing.

Performance was not impacted by the hrHPV genotype with increased detection in both HPV16 and non 16 hrHPV positive women.

Cervical cancer is the 7th most common disease globally, and the third most prevalent in woman. The disease is caused by the persistent high-risk human papillomavirus (HPV) infection, which triggers changes in the cervical cells.

Although colposcopy is an important method in detecting cervical cancer, in practice, the procedure has not drastically changed over the last 90 years, and diagnosis depends on the subjective assessment of visual indicators by the clinician. An objective assessment will help clinicians to better manage patients and help avoid unnecessary biopsies, treatments and repeat follow-up appointments.

Sameer Kothari, Chief Executive of Zilico Ltd, said: “ZedScan is now used in many hospitals across the globe as an adjunct to the current diagnostic process to offer a more accurate diagnosis in real time and assist clinicians with improved patient management.

“Colposcopy referrals are expected to increase dramatically following the introduction of HPV screening and ZedScan can provide a cost effective means to accommodate this growth. It can also increase compliance with hospital guidelines for performance and waiting times.”

Zilico will be located in Hall 16, Stand F18-5.

For more information visit: https://zilico.co.uk/

More Less

About us

Company details

Zilico Ltd is a UK company specialising in the design and manufacture of real-time medical diagnostics to address specific clinical needs.
ZedScan™, Zilico's pioneering flagship product utilises Electrical Impedance Spectroscopy (EIS) to improve the ability to detect cervical intraepithelial neoplasia (CIN) following an abnormal smear result, increasing diagnostic accuracy and delivering health economic benefits.
Zilico’s patented EIS technology exploits the different electrical resistivity associated with the cellular structure of normal, pre-cancerous and cancerous tissue, which based on its applicability to other types of neoplasia, substantiates its use as a platform for the rapid, reliable and reproducible detection and diagnosis of disease.

Zilico has a number of other products in development including  a screening test for cervical cancer and a diagnostic for oral dysplasia.

We are interested in meeting with companies who currently sell into the gynaecology and colposcopy markets, for potential distribution of ZedScan™.

More Less